An international collaboration led by Hilleman Laboratories has confirmed the launch of a new oral cholera vaccine called HILLCHOL, hoping to address significant global shortages.
Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation to support its vaccine development efforts.
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
The Australian biotech GPN Vaccines has expanded a partnership with compatriot contract development and manufacturing organization (CDMO) BioCina to scale up the manufacture of its lead candidate vaccine against pneumococcal diseases such as pneumonia,...
The UK has unveiled £34.5 million ($42.8 million) in funding for four hubs dedicated to the development of vaccines for diseases with epidemic potential in low- and middle-income countries (LMICs).
OrganaBio, a contract technology development and manufacturing organization (CTDMO) specializing in solutions for cell and immunotherapy development, has launched a new division.
OPKO Health’s ModeX Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.
The messenger RNA (mRNA) specialist Moderna has teamed up with ElevateBio-owned Life Edit Therapeutics to develop gene editing therapies that are delivered into patients in vivo.
BioNTech has dosed the first participant in a Phase 1 trial for BNT163, a herpes simplex virus (HSV) vaccine candidate for HSV-2 and potentially HSV-1.
ExPLoRNA Therapeutics, a Polish biotech developing mRNA vaccines and therapeutics with improved translational efficiency, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology.
Vaxxas has completed a financing round which raised US$23m (A$34m) in new funds: allowing the company to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities towards commercial scale.
Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.
EncOVac, a consortium led by Poolbeg Pharma, has been awarded €2.3m ($2.37m) in non-dilutive grant funding to progress its Oral Vaccine Platform under the Irish Government’s Disruptive Technologies Innovation Fund (‘DTIF’).
The US Food and Drug Administration (FDA) has granted Priority Review to GSK’s respiratory syncytial virus (RSV) older adult vaccine candidate with a decision expected in May 2023: which could make it the first vaccine approved against the virus.
CSL Limited has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings to access its late stage, next-generation self-amplifying mRNA (sa-mRNA) vaccine tech: prepared to spend more than $4bn on the deal to accelerate its...
Yapan Bio, a contract development and manufacturing organization (CDMO) based in India, says it can now support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.
The EU’s tailor-made centralised system for vaccine procurement was successful in procuring sufficient doses of COVID-19 vaccines, but a new report finds holes in the approach.
A collaboration between Touchlight and Lonza expands the Swiss CDMO’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material, the UK biotech’s doggybone DNA (dbDNA).
A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.
The US Centers for Disease Control and Prevention (CDC) says COVID-19 has ‘pushed back years of progress’ in combating antimicrobial resistance (AR) in the US – adding that the threat from AR has also got worse.
Moderna and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU) to establish a partnership for vaccine research and development.
Releasing its first-ever report on the pipeline of vaccines in development to prevent infections caused by antimicrobial-resistant (AMR) bacterial pathogens, the WHO is calling for more AMR vaccine development.
Moderna has dosed the first participant in a Phase 1 trial of its Nipah virus vaccine candidate, mRNA-1215, that has been developed in collaboration with the US National Institutes of Health (NIH).
A new type of vaccine - which could provide broad protection against a variety of SARS-like betacoronaviruses, including SARS-CoV-2 variants - has received backing of up to $30m from CEPI.
UK pharma group, Croda International, has inked a deal with the US government in which it will receive up to US$75m to expand its US manufacturing capacity for lipid systems.
Construction works on an mRNA manufacturing facility have started in Kigali, Rwanda: as BioNTech works to create a pan-African end-to-end manufacturing network for mRNA-based vaccines.
Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.
Pharma industry organizations say they are deeply disappointed by the decision taken by World Trade Organization (WTO) at its ministerial conference, MC12, to endorse a TRIPS waiver for COVID-19 vaccines.
Inventprise has inaugurated its new manufacturing facility for high-capacity supply of a 25-valent Pneumococcal Conjugate Vaccine (IVT-PCV-25) for low- and middle-income countries.
Last week the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a clinical trial to investigate a preventative vaccine for Epstein-Barr virus (EBV). It’s part of growing efforts to create...
The US will play a key role in the development of advanced manufacturing technologies, predicts a report commissioned by CPhI North America ahead of the 2022 show.
Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.
ReiThera and Exothera are partnering to develop what they call a large-scale, low cost per dose manufacturing process to deliver novel vaccines to low- and middle-income countries (LMICs).
The Bill & Melinda Gates Medical Research Institute is conducting a tuberculosis epidemiology study: setting the stage for a Phase 3 efficacy trial for its investigational tuberculosis vaccine.
eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the eTheRNA group, has introduced a new lipid nanoparticle (LNP) formulation, development and production service.
Exothera, a CDMO specializing in the industrialization of vaccine and gene therapy processes, reports that it has achieved GMP certification for its facilities in Jumet, Belgium.
Researchers at Australia’s national science agency, CSIRO, have developed a technique that protects vaccines at temperatures of up to 37 degrees Celsius: addressing the challenge of transporting vaccines to rural communities.
The selected companies, the inaugural cohort for MassBioDrive, get to participate in an eight-week program focused on growing businesses and advancing breakthrough science.
